Trial · NCT07886281
Humanitarian Evaluation of Spatial Emanators for Malaria Control
NCT07886281, Phase 4, Not yet recruiting, The Mentor Initiative
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Humanitarian Evaluation of Spatial Emanators for Malaria Control. Trials, record NCT07886281. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886281
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Humanitarian Evaluation of Spatial Emanators for Malaria Control
- NCT number
- NCT07886281
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 32,584 participants, estimated
- Lead sponsor
- The Mentor Initiative
- Conditions
- Malaria Infection
- Interventions
- Guardian™ long-lasting spatial emanators
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All-age malaria infection prevalence at 6 months following Phase 1 Guardian™ deployment | 6 months after Phase 1 Guardian™ deployment. | Percentage of randomly selected participants of all ages with a positive malaria rapid diagnostic test, irrespective of symptoms, calculated as the number with positive results divided by the number with valid results, multiplied by 100. Two separate Phase 1 comparisons will be conducted: Yida intervention versus Yida control, and Ajuong Thok intervention versus Pamir control. The effect measure will be the intervention-to-control prevalence ratio, adjusted for baseline malaria prevalence in the corresponding geographic sampling cluster and prespecified participant and household covariates. |
| Secondary | Indoor female Anopheles landing rate | Baseline and monthly during months 1-6 after distribution in each phase; baseline and monthly during months 1-3 for newly arriving refugees. | Number of female Anopheles mosquitoes collected indoors by human landing catches divided by indoor collection effort, expressed as mosquitoes per person-hour. Phase 1 analyses will compare baseline-to-post-distribution changes between intervention and control populations, pooling the two population comparison strata. Phase 2 and newly arriving refugee analyses will assess changes from their respective reference periods. |
| Secondary | Outdoor female Anopheles mosquito landing rate | Baseline and monthly during months 1-6 after distribution in each phase; baseline and monthly during months 1-3 for newly arriving refugees. | Number of female Anopheles mosquitoes collected outdoors by human landing catches divided by outdoor collection effort, expressed as mosquitoes per person-hour. Phase 1 analyses will compare baseline-to-post-distribution changes between intervention and control populations, pooling the two population comparison strata. Phase 2 and newly arriving refugee analyses will assess changes from their respective reference periods. |
| Other | Percentage of targeted households receiving Guardian™ within the planned distribution window | At completion of each distribution round, up to 2 weeks after the start of distribution, in Phases 1 and 2 | Number of targeted households documented as receiving Guardian™ within the prespecified distribution window divided by the total number of households targeted for that distribution, multiplied by 100. Receipt dates will be obtained from distribution registers and verified through household monitoring. Results will be reported by beneficiary group and implementation phase. |
| Other | Percentage of targeted households receiving at least one Guardian™ unit | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after distribution. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Percentage of sampled households in targeted intervention populations reporting receipt of at least one Guardian™ unit. Estimates will be obtained through repeated cross-sectional household surveys, supported by distribution records and direct observation where possible. Results will be reported separately for established camp residents, host communities and newly arriving refugees. |
| Other | Percentage of recipient households receiving an adequate number of Guardian™ units for shelter volume | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after distribution. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Number of recipient households receiving at least the number of Guardian™ units required for their measured shelter volume divided by the number of recipient households assessed, multiplied by 100. Required unit numbers will follow the manufacturer's dosing instructions, based on one unit per less than 15 cubic metres of shelter volume. |
| Other | Percentage of household respondents correctly identifying Guardian™'s purpose and key use instructions | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after distribution. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Percentage of interviewed adult household respondents who correctly identify Guardian™'s intended purpose of reducing mosquito exposure and describe at least two key use instructions. Instructions include unpacking/activation, appropriate placement, adequate unit numbers for shelter volume, continuous use, and safe handling or reporting procedures. |
| Other | Percentage of recipient households with correctly positioned Guardian™ units | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after distribution. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Percentage of assessed recipient households whose deployed Guardian™ units meet the manufacturer's placement instructions, determined through direct shelter observation using a standardized checklist. Placement will be assessed separately from whether the household received sufficient units for its shelter volume. |
| Other | Percentage of originally issued Guardian™ units retained and in use | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after receipt. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Number of originally issued Guardian™ units verified as remaining in use in the monitored household divided by the number originally issued to that household, multiplied by 100. Unit identifiers and repeated household observations will distinguish original units from replacements. Loss, transfer, removal, disposal and replacement will be recorded separately. |
| Other | Percentage of household respondents reporting a perceived benefit from Guardian™ use | Phase 1: 1-2 weeks and 1, 3, 6, 9 and 12 months after receipt. Phase 2: 1-2 weeks and 1, 3 and 6 months. New arrivals: 1-2 weeks and 1 and 3 months in each phase. | Percentage of interviewed household respondents reporting that Guardian™ use has provided a perceived benefit, such as reduced mosquito presence, biting or nuisance. Structured survey responses will be complemented by interviews and focus group discussions exploring the nature of perceived benefits. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886281
GET https://conductscience.org/api/trials/v1/NCT07886281/registered